Off-label use of biologic agents in the treatment of dermatosis, part 2: Etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab;Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: Etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab

Actas Dermo-Sifiliograficas

Volumn 99, Issue 1, 2008, Pages 5-33

  Guhl Milán, Guillermo ^a   Diaz Ley B ^a   Fernandez Herrera J ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Biologic agents; Dermatosis; Off label use

Indexed keywords

ALEFACEPT; BASILIXIMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; EFALIZUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID; OMALIZUMAB; PREDNISOLONE; RITUXIMAB;

ALOPECIA AREATA; AMYLOIDOSIS; APHTHOUS STOMATITIS; BEHCET DISEASE; DERMATOMYOSITIS; DRUG EFFICACY; GRANULOMA ANNULARE; HUMAN; LUPUS ERYTHEMATOSUS; NECROBIOSIS LIPOIDICA; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; PYODERMA GANGRENOSUM; RETICULOHISTIOCYTOSIS; REVIEW; SAPHO SYNDROME; SARCOIDOSIS; SCLERODERMA; SKIN DISEASE; WEGENER GRANULOMATOSIS;

EID: 39049090394     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(08)74612-X     Document Type: Review

References (284)

1. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56:e55-79.
2. Kerns MJ, Graves JE, Smith DI, Heffernan MP. Off-label uses of biologic agents in dermatology: a 2006 update. Semin Cutan Med Surg. 2006;25:226-40.
3. Jacobi A, Manger B, Schuler G, Hertl M. [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]. J Dtsch Dermatol Ges. 2003;1:259-72.
4. Trent JT, Kerdel FA. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs. 2005;17(2):97-107.
5. Williams JD, Griffiths CE. Cytokine blocking agents in dermatology. Clin Exp Dermatol. 2002;27:585-90.
6. Scheinfeld N. The medical uses and side effects of etanercept with a focus on cutaneous disease. J Drugs Dermatol. 2004;3:653-9.
7. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg. 2005;9:296-302.
8. Gamo R, López-Estebaranz JL. Biologic therapy and psoriasis. Actas Dermosifiliogr. 2006;97:1-17.
9. Nanda S, Bathon JM. Et anercept: a clinical review of current and emerging indications. Expert Opin Pharmacother. 2004;5:1175-86.
10. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol. 2003;49Suppl:S105-11.
11. Goffe B. Etanercept (Enbrel) - an update. Skin Therapy Lett. 2004;9:1-4, 9.
12. http://emea.europa.eu/humandocs/Humans/EPAR/enbrel/enbrel.htm.
13. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol. 2004;16(4):393-8.
14. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167-79.
15. Swale VJ, Perrett CM, Denton CP, Black CM, Rustin MH. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003;28:604-7.
16. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-80.
17. Richez C, Blanco P, Dumoulin C, Schaeverbeke T. Lupus erythematosus manifestations exacerbated by etanercept therapy in a patient with mixed connective tissue disease. Clin Exp Rheumatol. 2005;23:273.
18. Mor A, Bingham C, Barisoni L, Lydon E, Belmont HM. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. J Rheumatol. 2005;32:740-3.
19. Lepore L, Marchetti F, Facchini S, Leone V, Ventura A. Drug-induced systemic lupus erythematosus associated with etanercept therapy in a child with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2003;21:276-7.
20. Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006;21:946-9.
21. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol. 2003;22:56-61.
22. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545-51.
23. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003;48:1165-6; author reply 1166.
24. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002;61:1031-2.
25. Bleumink GS, ter Borg EJ, Ramselaar CG, Ch Stricker BH. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford). 2001;40:1317-9.
26. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol. 2005;11:47-9.
27. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006;54Suppl2:S139-42.
28. Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum. 2002;46:1408-9; author reply 1409.
29. Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 2006;55:982-4.
30. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006;65:1233-6.
31. Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33:1802-4.
32. Ellman MH MP, HAyes FA. Etanercept as treatment for diffuse scleroderma: a pilot study. Arthritis Rheum. 2000;43:392.
33. Yamauchi PS, Turner L, Lowe NJ, Gindi V, Jackson JM. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol. 2006;54Suppl2: S122-6.
34. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152:1059-61.
35. Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006;54Suppl2:S128-34.
36. McGowan JWt, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol. 2004;3:441-4.
37. Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat. 2005;16:347-9.
38. Pastor N, Betlloch I, Pascual JC, Blanes M, Banuls J, Silvestre JF. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol. 2006;31:152-3.
39. Disla E, Quayum B, Cuppari GG, Pancorbo R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin Rheumatol. 2004;10:50-2.
40. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011-6.
41. Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermuller J, Thierfelder S, Kaul M, et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc. 1993;25:1234-6.
42. Holler E, Kolb HJ, Eissner G, Wilmanns W. Cytokines in GvH and GvL. Bone Marrow Transplant. 1998;22Suppl4:S3-6.
43. Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood. 2003;101:2440-5.
44. Jacobsohn DA, Vogelsang GB. Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des. 2004;10:1195-205.
45. Andolina M, Rabusin M, Maximova N, Di Leo G. Etanercept in graft-versus-host disease. Bone Marrow Transplant. 2000;26:929.
46. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant. 2005;35:1003-10.
47. Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant. 2006;37:1143-7.
48. Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:680-7.
49. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82:45-52.
50. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation. 2002;73:665-7.
51. Ogden S, Clayton TH, Goodfield MJ. Recalcitrant hand pompholyx: variable response to etanercept. Clin Exp Dermatol. 2006;31:145-6.
52. Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol. 2005;53:358-9.
53. Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol. 2006;54Suppl2:S121-2.
54. Sacher C, Rubbert A, Konig C, Scharffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol. 2002;46:113-5.
55. Prey S, Robert PY, Drouet M, Sparsa A, Roux C, Bonnetblanc JM, et al. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Acta Derm Venereol. 2007;87:74-5.
56. Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol. 2006;142:1457-61.
57. Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol. 2005;141:680-2.
58. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis. 2004;74:245-7.
59. Gubinelli E, Bergamo F, Didona B, Annessi G, Atzori F, Raskovic D. Pemphigus foliaceus treated with etanercept. J Am Acad Dermatol. 2006;55:1107-8.
60. Utz JP, Limper AH, Kalra S, Specks U, Scott JP, Vuk-Pavlovic Z, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest. 2003;124:177-85.
61. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128:1062-47.
62. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol. 2003;30:1864-7.
63. Tuchinda C, Wong HK. Etanercept for chronic progressive cutaneous sarcoidosis. J Drugs Dermatol. 2006;5:538-40.
64. González-López MA, Blanco R, González-Vela MC, Fernández-Llaca H, Rodríguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum. 2006;55:817-20.
65. Kudrin A, Chilvers ER, Ginawi A, Hazleman BL, Griffiths MH, Thiru S, et al. Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol. 2007;34:648-9.
66. Verschueren K, Van Essche E, Verschueren P, Taelman V, Westhovens R. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. Clin Rheumatol. 2007;26:1969-71.
67. Shupack J, Siu K. Resolving granuloma annulare with etanercept. Arch Dermatol. 2006;142:394-5.
68. Kreuter A, Altmeyer P, Gambichler T. Failure of etanercept therapy in disseminated granuloma annulare. Arch Dermatol. 2006;142:1236-7.
69. Cummins DL, Hiatt KM, Mimouni D, Vander Kolk CA, Cohen BA, Nousari CH. Generalized necrobiosis lipoidica treated with a combination of split-thickness autografting and immunomodulatory therapy. Int J Dermatol. 2004;43:852-4.
70. Zeichner JA, Stern DW, Lebwohl M. Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol. 2006;54Suppl 2:S120-1.
71. Pasternack FR, Fox LP, Engler DE. Silicone granulomas treated with etanercept. Arch Dermatol. 2005;141:13-5.
72. Desai AM, Browning J, Rosen T. Etanercept therapy for silicone granuloma. J Drugs Dermatol. 2006;5:894-6.
73. Rapaport MJ. Silicone granulomas treated with etanercept. Arch Dermatol. 2005;141:1171.
74. Lin JH, Liebhaber M, Roberts RL, Dyer Z, Stiehm ER. Etanercept treatment of cutaneous granulomas in common variable immunodeficiency. J Allergy Clin Immunol. 2006;117:878-82.
75. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98-105.
76. Sommer A, Altmeyer P, Kreuter A. A case of mucocutaneous Behcet's disease responding to etanercept. J Am Acad Dermatol. 2005;52:717-9.
77. Atzeni F, Sarzi-Puttini P, Capsoni F, Mecchia M, Marrazza MG, Carrabba M. Successful treatment of resistant Behcet's disease with etanercept. Clin Exp Rheumatol. 2005;23:729.0
78. Estrach C, Mpofu S, Moots RJ. Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford). 2002;41:1213-4.
79. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001;44:1149-54.
80. Wegener's granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351-61.
81. Kleinert J, Lorenz M, Kostler W, Horl W, Sunder-Plassmann G, Soleiman A. [Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade]. Wien Klin Wochenschr. 2004;116:334-8.
82. Feinstein J, Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol. 2005;11:219-22.
83. Kovach BT, Calamia KT, Walsh JS, Ginsburg WW. Treatment of multicentric reticulohistiocytosis with etanercept. Arch Dermatol. 2004;140:919-21.
84. Lovelace K, Loyd A, Adelson D, Crowson N, Taylor JR, Cornelison R. Etanercept and the treatment of multicentric reticulohistiocytosis. Arch Dermatol. 2005;141:1167-8.
85. Matejicka C, Morgan GJ, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum. 2003;48:864-6.
86. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153:241-53.
87. Famularo G, Di Dona B, Canzona F, Girardelli CR, Cruciani G. Etanercept for toxic epidermal necrolysis. Ann Pharmacother. 2007;41:1083-4.
88. Campione E, Mazzotta AM, Bianchi L, Chimenti S. Severe acne successfully treated with etanercept. Acta Derm Venereol. 2006;86:256-7.
89. Cortis E, De Benedetti F, Insalaco A, Cioschi S, Muratori F, D'Urbano LE, et al. Abnormal production of tumor necrosis factor (TNF) - alpha and clinical efficacy of the TNF inhibitor etanercept in a patient with PAPA syndrome [corrected]. J Pediatr. 2004;145:851-5.
90. Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154:726-9.
91. Henderson RL, Jr. Case reports: treatment of atypical hidradenitis suppurativa with the tumor necrosis factor receptor-Fc fusion protein etanercept. J Drugs Dermatol. 2006;5:1010-1.
92. Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol. 2003;139:1259-62.
93. Strober BE, Siu K, Alexis AF, Kim G, Washenik K, Sinha A, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol. 2005;52:1082-4.
94. Abramovits W, Losornio M. Failure of two TNF-alpha blockers to influence the course of alopecia areata. Skinmed. 2006;5:177-81.
95. Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol. 2005;141:759-60.
96. Minni J, Sarro R. A novel therapeutic approach to erythema annulare centrifugum. J Am Acad Dermatol. 2006;54Suppl 2:S134-5.
97. Hussein MA, Juturi JV, Rybicki L, Lutton S, Murphy BR, Karam MA. Etanercept therapy in patients with advanced primary amyloidosis. Med Oncol. 2003;20:283-90.
98. Querfeld C, Guitart J, Kuzel TM, Rosen S. Successful treatment of recalcitrant, erythroderma-associated pruritus with etanercept. Arch Dermatol. 2004;140:1539-40.
99. Tsimberidou AM, Giles FJ, Duvic M, Kurzrock R. Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. J Am Acad Dermatol. 2004;51:200-4.
100. Bogle MA, Sobell JM, Dover JS. Successful treatment of a widespread inflammatory verrucous epidermal nevus with etanercept. Arch Dermatol. 2006;142:401-2.
101. Wagner AD, Andresen J, Jendro MC, Hulsemann JL, Zeidler H. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum. 2002;46:1965-8.
102. van Noesel C, Miedema F, Brouwer M, de Rie MA, Aarden LA, van Lier RA. Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature. 1988;333:850-2.
103. Shear NH, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg. 2006;9Suppl1:4-9.
104. http://emea.europa.eu/humandocs/Humans/EPAR/raptiva/raptiva.htm. Consultado 30 junio 2007.
105. Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005;27:1317-28.
106. Goffe BS. Disseminated granuloma annulare resolved with the T-cell modulator efalizumab. Arch Dermatol. 2004;140:1287-8.
107. Cheng A, Mann C. Oral erosive lichen planus treated with efalizumab. Arch Dermatol. 2006;142:680-2.
108. Heffernan MP, Smith DI, Bentley D, Tabacchi M, Graves JE. A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus. J Drugs Dermatol. 2007;6:310-4.
109. Bohm M, Luger TA. Lichen planus responding to efalizumab. J Am Acad Dermatol. 2007;56Suppl:S92-3.
110. Weinberg JM, Siegfried EC. Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab. Arch Dermatol. 2006;14:555-8.
111. Hassan AS, Kaelin U, Braathen LR, Yawalkar N. Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. J Am Acad Dermatol. 2007;56:217-21.
112. Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol. 2007;56:222-7.
113. Huber A, Gaffal E, Bieber T, Tuting T, Wenzel J. Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm Venereol. 2006;86:254-5.
114. Dedrick RL, Walicke P, Garovoy M. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol. 2002;9:181-6.
115. McMichael AJ. The new biologics in psoriasis: possible treatments for alopecia areata. J Investig Dermatol Symp Proc. 2003;8:217-8.
116. Kaelin U, Hassan AS, Braathen LR, Yawalkar N. Treatment of alopecia areata partim universalis with efalizumab. J Am Acad Dermatol. 2006;55:529-32.
117. Tosti A, Pazzaglia M, Starace M, Bellavista S, Vincenzi C, Tonelli G. Alopecia areata during treatment with biologic agents. Arch Dermatol. 2006;142:1653-4.
118. Clayton TH, Ogden S, Goodfield MD. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol. 2006;54:892-5.
119. Bentley DD, Graves JE, Smith DI, Heffernan MP. Efalizumab-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2006;54Suppl:S242-3.
120. Usmani N GM. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol. 2007;143:873-7.
121. http://www.fda.gov/cder/biologics/products/alefbio013003.htm. Consultado 30 junio 2007.
122. Hodak E, David M. Alefacept: a review of the literature and practical guidelines for management. Dermatol Ther. 2004;17:383-92.
123. Fivenson DP, Mathes B. Treatment of generalized lichen planus with alefacept. Arch Dermatol. 2006;142:151-2.
124. Heffernan MP, Hurley MY, Martin KS, Smith DI, Anadkat MJ. Alefacept for alopecia areata. Arch Dermatol. 2005;141:1513-6.
125. García-Zuazaga J, Korman NJ. Cutaneous sarcoidosis successfully treated with alefacept. J Cutan Med Surg. 2006;10:300-3.
126. Chi GC, Hsu FS, Yang CC, Wei JC. Scleroderma and failed response to alefacept. Rheumatology (Oxford). 2005;44:1328-30.
127. Shapira MY, Resnick IB, Bitan M, Ackerstein A, Tsirigotis P, Gesundheit B, et al. Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant. 2005;36:1097-101.
128. Grillo-López AJ, White CA, Varns C, Shen D, Wei A, McClure A, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26Suppl14:66-73.
129. http://www.emea.europa.eu/humandocs/Humans/EPAR/mabthera/mabthera.htm.
130. Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-74.
131. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-95.
132. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900-8.
133. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, Solal-Celigny P, Ghielmini M, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-24.
134. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706-14.
135. Mohrbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res Ther. 2005;7Suppl3:S19-25.
136. Pérez-Gala S, Delgado-Jiménez Y, Goiriz R, Fraga J, García-Díez A, Fernández-Herrera J. Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma. Arch Dermatol. 2006;142:1516-7.
137. Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000;89:1835-44.
138. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-400.
139. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580-9.
140. Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54:3612-22.
141. Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol. 2004;16:180-5.
142. Looney RJ. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford). 2005;44Suppl2:ii13-7.
143. Looney RJ. B cell-targeted therapy in diseases other than rheumatoid arthritis. J Rheumatol Suppl. 2005;73:25-8.
144. Looney RJ, Anolik J, Sanz I. Treatment of SLE with anti-CD20 monoclonal antibody. Curr Dir Autoimmun. 2005;8:193-205.
145. Tahir H, Rohrer J, Bhatia A, Wegener WA, Isenberg DA. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford). 2005;44:561-2.
146. Lehembre S, Macario-Barrel A, Musette P, Carvalho P, Joly P. Rituximab treatment for immune thrombocytopenia associated with systemic lupus erythematosus. Ann Dermatol Venereol. 2006;133:53-5.
147. Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007;17:191-7.
148. Sabugo F, Llanos C, Soto L, Gutiérrez J, Cuchacovich M. Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case. Rev Med Chil. 2005;133:681-4.
149. Saito K, Nawata M, Iwata S, Tokunaga M, Tanaka Y. Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:1462-4.
150. Van den Bergh B, Selleslag D, Boelaert JR, Matthys EG, Schurgers M, Vandecasteele S, et al. Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature. Acta Clin Belg. 2005;60:102-5.
151. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology. 2002;206:519-27.
152. Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford). 2005;44:176-82.
153. Saigal K, Valencia IC, Cohen J, Kerdel FA. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol. 2003;49Suppl:S283-5.
154. Greenberg SA, Amato AA. Uncertainties in the pathogenesis of adult dermatomyositis. Curr Opin Neurol. 2004;17:359-64.
155. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-7.
156. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143:763-7.
157. Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol. 2007;56:148-53.
158. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006;33:1021-6.
159. Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol. 2005;11:264-6.
160. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:262-8.
161. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med. 2005;257:540-8.
162. Ferraro AJ, Day CJ, Drayson MT, Savage CO. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant. 2005;20:622-5.
163. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001;44:2836-40.
164. Memet B, Rudinskaya A, Krebs T, Oelberg D. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. J Clin Rheumatol. 2005;11:314-8.
165. Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542.
166. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol. 2005;34:229-32.
167. Bachmeyer C, Cadranel JF, Demontis R. Rituximab is an alternative in a case of contra-indication of cyclophosphamide in Wegener's granulomatosis. Nephrol Dial Transplant. 2005;20:1274.
168. Tamura N, Matsudaira R, Hirashima M, Ikeda M, Tajima M, Nawata M, et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med. 2007;46:409-14.
169. Kallenbach M, Duan H, Ring T. Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract. 2005;99:92-6.
170. Tektonidou MG, Skopouli FN. Sustained 3-year remission after rituximab treatment in a patient with refractory Wegener's granulomatosis. Clin Exp Rheumatol. 2006;24Suppl41:S103.
171. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2006;45:1432-6.
172. Henes JC, Fritz J, Koch S, Klein R, Horger M, Risler T, et al. Rituximab for treatment-resistant extensive Wegener;s granulomatosis-additive effects of a maintenance treatment with leflunomide. Clin Rheumatol. 2007. 26:1711-5.
173. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173:180-7.
174. Aries PM, Hellmich B, Voswinkel J, Both M, Nolle B, Holl-Ulrich K, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. 2006;65:853-8.
175. Aries PM, Lamprecht P, Gross WL. Rituximab in refractory Wegener's granulomatosis: Favorable or not? Am J Respir Crit Care Med. 2006;173:815-6.
176. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol. 2007;25Suppl44:S23-7.
177. Chu D, Stevens M, Gladstone DE. Severe, refractory, nonmalignant type I cryoglobulinemia treated with alemtuzumab. Rheumatol Int. 2007.27:1173-5.
178. Nehme-Schuster H, Korganow AS, Pasquali JL, Martin T. Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology (Oxford). 2005;44:410-1.
179. Mantha S, Jacobs MI, Savage DG. Unusual leukemia presentations. Case 3. Type I IgGlambda cryoglobulinemia associated with chronic lymphocytic leukemia. J Clin Oncol. 2005;23:5841-3.
180. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101:3818-26.
181. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101:3827-34.
182. Zaja F, De Vita S, Russo D, Michelutti A, Fanin R, Ferraccioli G, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum. 2002;46:2252-4; author reply 2254-5.
183. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica. 1999;84:1157-8.
184. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis. 2002;61:922-4.
185. Cai FZ, Ahern M, Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol. 2006;33:1197-8.
186. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis. 2004;43:e34-8.
187. Koukoulaki M, Abeygunasekara SC, Smith KG, Jayne DR. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant. 2005;20:213-6.
188. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62:1230-3.
189. Cohen H, Green S, Jones S, Amos N, William BD. Lack of efficacy of rituximab in a patient with essential mixed cryoglobulinaemia. Rheumatology (Oxford). 2007;46:366-7.
190. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002;47:785-8.
191. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory Pemphigus vulgaris: report of a case. Haematologica. 2003;88:24.
192. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol. 2003;28:366-8.
193. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003;148:602-3.
194. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51:817-9.
195. Espana A, Fernández-Galar M, Lloret P, Sánchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004;50:974-6.
196. Dupuy A, Viguier M, Bedane C, Cordoliani F, Blaise S, Aucouturier F, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140:91-6.
197. Cecchi R, Gasperini U. Severe pemphigus vulgaris treated with rituximab (Mabthera). J Dermatol. 2005;32:862-4.
198. Kong HH, Prose NS, Ware RE, Hall RP, 3rd. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol. 2005;22:461-4.
199. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153:620-5.
200. Schmidt E, Herzog S, Brocker EB, Zillikens D, Goebeler M. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol. 2005;153:449-51.
201. Wenzel J, Bauer R, Bieber T, Tuting T. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol. 2005;85:185-6.
202. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772-9.
203. Domínguez-Fernández I, Pérez-Gala S, Goiriz R, Sánchez-Pérez J, Fernández-Herrera J. [Pemphigus vulgaris treated with rituximab]. Actas Dermosifiliogr. 2006;97:221-2.
204. Niedermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol. 2006;16:266-70.
205. Esposito M, Capriotti E, Giunta A, Bianchi L, Chimenti S. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol. 2006;86:87-9.
206. Pitarch G, Sánchez-Carazo JL, Pardo J, Torrijos A, Roche E, Fortea JM. [Treatment of severe refractory pemphigus vulgaris with rituximab]. Actas Dermosifiliogr. 2006;97:48-51.
207. Belgi AS, Azeez M, Hoyle C, Williams RE. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol. 2006;31:143.
208. Antonucci A, Negosanti M, Tabanelli M, Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): Five cases. J Dermatolog Treat. 2007;18:178-83.
209. Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology. 2007;214:310-8.
210. Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol. 2007;156:990-6.
211. Borel C, Launay F, Garrouste C, Astudillo L, Bazex J, Arlet P, et al. [Rituximab induced remission of pemphigus vulgaris: 2 cases]. Rev Med Interne. 2007;28:266-8.
212. Schmidt E, Seitz CS, Benoit S, Brocker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156:352-6.
213. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66:142-4.
214. Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hugli A. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137:269-72.
215. Gergely L, Varoczy L, Vadasz G, Remenyik E, Illes A. Successful treatment of B cell chronic lymphocytic leukemia-associated severe paraneoplastic pemphigus with cyclosporin A. Acta Haematol. 2003;109:202-5.
216. Rossum MM, Verhaegen NT, Jonkman MF, Mackenzie MA, Koster A, Van Der Valk PG, et al. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leuk Lymphoma. 2004;45:2327-32.
217. Imataki O, Tamai Y, Abe Y, Ito I, Yoshikawa S, Kawakami K. [A case of follicular lymphoma complicated with lethal pemphigus]. Gan To Kagaku Ryoho. 2006;33:1677-80.
218. Barnadas M, Roe E, Brunet S, García P, Bergua P, Pimentel L, et al. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol. 2006;20:69-74.
219. Hoque SR, Black MM, Cliff S. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin Exp Dermatol. 2007;32:172-5.
220. Taintor AR, Leiferman KM, Hashimoto T, Ishii N, Zone JJ, Hull CM. A novel case of IgA paraneoplastic pemphigus associated with chronic lymphocytic leukemia. J Am Acad Dermatol. 2007;56Suppl:S73-6.
221. Goebeler M, Herzog S, Brocker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003;149:899-901.
222. Connelly EA, Aber C, Kleiner G, Nousari C, Charles C, Schachner LA. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment. Pediatr Dermatol. 2007;24:172-6.
223. McGinness JL, Bivens MM, Greer KE, Patterson JW, Saulsbury FT. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J Am Acad Dermatol. 2006;55:143-8.
224. Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007;156:194-6.
225. Niedermeier A, Eming R, Pfutze M, Neumann CR, Happel C, Reich K, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007;143:192-8.
226. Schmidt E, Benoit S, Brocker EB, Zillikens D, Goebeler M. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol. 2006;142:147-50.
227. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed AR. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A. 1995;92:5239-43.
228. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003;2:564-7.
229. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505-11.
230. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation. 1988;46:238-40.
231. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002;109:1453-62.
232. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004;104:2603-6.
233. Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Takenaka H, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006;20:172-3.
234. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756-62.
235. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, et al. Treatment of refractory chronic GVHD with Rituximab: a GITMO study. Bone Marrow Transplant. 2007;40:273-7.
236. Kamble R, Oholendt M, Carrum G. Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12:1201-2.
237. Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med. 2000;133:275-9.
238. Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 2002;30:327-9.
239. Carella AM, Biasco S, Nati S, Congiu A, Lerma E. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease. Leuk Lymphoma. 2007;48:623-4.
240. Milgrom H, Fick RB, Jr., Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 1999;341:1966-73.
241. http://emea.europa.eu/humandocs/Humans/EPAR/xolair/xolair.htm. Consultado 30 junio 2007.
242. Leynadier F, Doudou O, Gaouar H, Le Gros V, Bourdeix I, Guyomarch-Cocco L, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol. 2004;113:360-1.
243. Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. Jama. 2001;286:2956-67.
244. Kaliner MA. Omalizumab and the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2004;4:237-44.
245. Okubo K, Ogino S, Nagakura T, Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006;55:379-86.
246. Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol. 2005;29:31-48.
247. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol. 2006;96:624-7.
248. Lanier BQ. Unanswered questions and warnings involving anti-immunoglobulin E therapy based on 2-year observation of clinical experience. Allergy Asthma Proc. 2005;26:435-9.
249. Scheinfeld N. Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. Dermatol Online J. 2005;11:2.
250. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-61.
251. http://emea.europa.eu/humandocs/PDFs/EPAR/Xolair/H-606-PI-es.pdf. Consultado 30 junio 2007.
252. Schmitt J, Schakel K. Omalizumab as a therapeutic option in atopic eczema. Current evidence and potential benefit. Hautarzt. 2007;58:128, 130-2.
253. Johansson SG, Haahtela T, O'Byrne PM. Omalizumab and the immune system: an overview of preclinical and clinical data. Ann Allergy Asthma Immunol. 2002;89:132-8.
254. Simpson EL, Hanifin JM. Atopic dermatitis. J Am Acad Dermatol. 2005;53:115-28.
255. Beck LA, Saini S. Wanted: A study with omalizumab to determine the role of IgE-mediated pathways in atopic dermatitis. J Am Acad Dermatol. 2006;55:540-1.
256. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338-40.
257. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006;54:68-72.
258. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55:168-70.
259. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol. 2007;119:1550-1.
260. Mankad VS, Burks AW. Omalizumab: other indications and unanswered questions. Clin Rev Allergy Immunol. 2005;29:17-30.
261. http://emea.europa.eu/humandocs/PDFs/EPAR/Zenapax/H-198-PI-es.pdf. Consultado 30 junio 2007.
262. Mockenhaupt M, Grosber M, Norganer J. Daclizumab: a novel therapeutic option in severe bullous pemphigoid. Acta Derm Venereol. 2005;85:65-6.
263. Renkl A, Mockenhaupt M, Technau K, Herouy Y, Norgauer J. A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody. Br J Dermatol. 2004;150:1220-2.
264. Egan CA, Brown M, White JD, Yancey KB. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab. Clin Immunol. 2001;101:146-51.
265. Osborne GE, Pagliuca A, Ho A, du Vivier AW. Novel treatment of Sezary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody). Br J Dermatol. 2006;155:617-20.
266. Krueger JG, Walters IB, Miyazawa M, Gilleaudeau P, Hakimi J, Light S, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol. 2000;43:448-58.
267. Wohlrab J, Fischer M, Taube KM, Marsch WC. Treatment of recalcitrant psoriasis with daclizumab. Br J Dermatol. 2001;144:209-10.
268. Dichmann S, Mrowietz U, Schopf E, Norgauer J. Humanized monoclonal anti-CD25 antibody as a novel therapeutic option in HIV-associated psoriatic erythroderma. J Am Acad Dermatol. 2002;47:635-6.
269. http://emea.europa.eu/humandocs/PDFs/EPAR/Simulect/H-207-PI-es.pdf. Consultado 30 junio 2007.
270. Haufs MG, Haneke E. Epidermolysis bullosa acquisita treated with basiliximab, an interleukin-2 receptor antibody. Acta Derm Venereol. 2001;81:72.
271. Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol. 1998;38:938-44.
272. Owen CM, Harrison PV. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin Exp Dermatol. 2000;25:195-7.
273. Bell HK, Parslew RA. Use of basiliximab as a cyclosporin-sparing agent in palmoplantar pustular psoriasis with myalgia as an adverse effect. Br J Dermatol. 2002;147:606-7.
274. Mrowietz U, Zhu K, Christophers E. Treatment of severe psoriasis with anti-CD25 monoclonal antibodies. Arch Dermatol. 2000;136:675-6.
275. Salim A, Emerson RM, Dalziel KL. Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker). Br J Dermatol. 2000;143:1121-2.
276. Rebora A, Parodi A, Murialdo G. Basiliximab is effective for erosive lichen planus. Arch Dermatol. 2002;138:1100-1.
277. Guhl G, González-de Arriba A, Dauden E. [Epidermal growth factor receptor inhibitors side effects]. Actas Dermosifiliogr. 2006;97:296-310.
278. http://emea.europa.eu/humandocs/Humans/EPAR/erbitux/erbitux.htm. Consultado 30 junio 2007.
279. http://emea.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-PI-es.pdf. Consultado 30 junio 2007.
280. Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007;18:827-9.
281. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007;1:889-92.
282. http://clinicaltrials.gov/ct/show/NCT00240682? Consultado 30 julio 2007.
283. Ben-Bassat H. Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr Opin Investig Drugs. 2001;2:1539-45.
284. Mueller H, Eisendle K, Fritsch P. Basal-cell carcinoma. N Engl J Med. 2006;354:769-71.